688488.SS
EquityJIANGSU AIDEA PHARMACEUTICAL GP
Health Care · Biotechnology
$16.82
+16.82 (+0.00%)
Open
N/A
Day Range
$16.23 - $17.48
52W Range
$8.20 - $22.55
Volume
12M
Price History
Key Statistics
Market Cap
N/A
P/E Ratio
N/A
EPS
N/A
Dividend Yield
N/A
P/B Ratio
N/A
Payout Ratio
N/A
ROE
N/A
Debt/Equity
N/A
Insider Activity
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Dec 27, 2024 |
Fu (Heliang) Chairman of the Board |
Other | 233,791 | $306.2K |
| Dec 27, 2024 |
Zhange (Jie) Chief Executive Officer |
Other | 82,856 | $108.5K |
| Dec 27, 2024 |
Fu (Heliang) Chairman of the Board |
Other | 233,791 | $306.2K |
| Dec 27, 2024 |
Zhange (Jie) Chief Executive Officer |
Other | 82,856 | $108.5K |
| Dec 27, 2024 |
Fu (Heliang) Chairman of the Board |
Other | 233,791 | $306.2K |
| Dec 27, 2024 |
Zhange (Jie) Chief Executive Officer |
Other | 82,856 | $108.5K |
| Dec 27, 2024 |
Fu (Heliang) Chairman of the Board |
Other | 233,791 | $306.2K |
| Dec 27, 2024 |
Zhange (Jie) Chief Executive Officer |
Other | 82,856 | $108.5K |
| Oct 22, 2024 |
Wang (Jun) Chief Operating Officer |
Sell | 623,760 | $800.3K |
| Oct 22, 2024 |
Wang (Jun) Chief Operating Officer |
Sell | 623,760 | $800.3K |
Institutional Ownership
Peers in Health Care
| Symbol | Name | Price | Mkt Cap | Div Yield | Change |
|---|---|---|---|---|---|
| A | Agilent Technologies, Inc. | $121.38 | N/A | 0.82% | +0.00% |
| ACB | Aurora Cannabis Inc. | $3.84 | N/A | - | +0.00% |
| AGEN | Agenus Inc. | $3.33 | N/A | - | +0.00% |
| ACAD | ACADIA Pharmaceuticals Inc. | $24.56 | N/A | - | +0.00% |
| AKBA | Akebia Therapeutics, Inc. | $1.31 | N/A | - | +0.00% |
| ABUS | Arbutus Biopharma Corporation | $4.66 | N/A | - | +0.00% |
| 001540.KQ | AHN-GOOK PHA | $8,070.00 | N/A | 5.45% | +0.00% |
| ABBV | AbbVie Inc. | $232.08 | N/A | 2.87% | +0.00% |
About JIANGSU AIDEA PHARMACEUTICAL GP
Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. The company offers anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products. The company was formerly known as Jiangsu Aidea Pharmaceutical Co., Ltd. and changed its name to Jiangsu Aidea Pharmaceutical Group Co., Ltd. in July 2025. The company was founded in 2009 and is headquartered in Yangzhou, China.
www.aidea.com.cn →🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Unsafe
Based on 4 fundamental factors
Analysis Tools
Share
Dividend History
🐂 Bull Score
Our proprietary rating measures dividend reliability based on 6 fundamental factors including payout sustainability, financial strength, and cash flow coverage.
Very Risky
Bull Score
Dividend Safety
Assessment based on payout ratio, debt levels, profit margins, and dividend growth track record.
Unsafe
Based on 4 fundamental factors
Loading financial data...
Revenue & Earnings
No financial statement data available for 688488.SS.